Sierra Health and Life spinal fusion Coverage Update

Coverage Criteria and Evidence Summary

Covered Products and Indications

Covered when ALL of the following are met for specific products:

InFUSE lumbar interbody indication: InFUSE (rhBMP-2) is proven and medically necessary for lumbar spine when: the approach is anterior or oblique and used in conjunction with an FDA‑approved interbody fusion device; the patient is skeletally mature (18 years or older or radiographic evidence of epiphyseal closure) with degenerative disc disease; the fusion involves vertebral bodies L2–S1 with spondylolisthesis no greater than grade 1 (≤25% displacement); and the fusion is single level.all conditions

Supported by policy language specifying FDA‑approved Infuse indications.

InFUSE/MASTERGRAFT posterolateral revision: InFUSE/MASTERGRAFT Posterolateral Revision Device System (or InFUSE BMP used with MASTERGRAFT) is medically necessary when all of the following are met: implanted via a posterolateral approach; symptomatic posterolateral lumbar pseudoarthrosis is present; the patient is skeletally mature (older than 21 years or radiographic evidence of epiphyseal closure); and autologous bone and/or bone marrow harvest is not feasible or is not expected to promote fusion.all conditions

Matches device‑specific posterolateral revision criteria in policy.

Proven allograft/synthetic categories: Proven and medically necessary options for enhancement of spinal fusion include: autografts (including bone marrow aspirate/BMA); demineralized bone matrix (DBM) when not containing additives listed as unproven; allograft‑based products not listed as unproven; ceramic‑based products (e.g., beta‑tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or BMA; bioactive glass used alone or with grafts/BMA; and expandable interbody fusion systems when used per applicable device indications and supporting evidence.any of listed products

Reflects the list of proven/medically necessary graft categories in the policy.

Unproven / Not Medically Necessary

Not covered / unproven due to insufficient evidence:

Cell-based allograft products: Cell‑based allograft products (for example, those containing mesenchymal stem cells, osteoblasts, or pre‑osteoblasts) are considered unproven and not medically necessary for spinal fusion because published clinical literature is limited, of very low quality, and does not permit conclusions regarding comparative safety or effectiveness to autograft (ICBG).evidence insufficient

Evidentiary assessments (ECRI, systematic reviews) report very low–quality and inconclusive data for CBAs.

Human amniotic tissue materials, including amniotic fluid stem cell substitutes, are listed as unproven and not medically necessary for enhancement of spinal fusion due to insufficient evidence of efficacy and safety.evidence insufficient

Policy enumerates amniotic products among unproven allograft‑based categories.

Specific named products lacking evidence: Specific commercial products lacking adequate published comparative evidence (examples cited in the policy include Trinity Elite, OsteoAMP, Bio4, PrimaGen, and certain proprietary or minimally processed allogeneic products) are considered unproven and not medically necessary until sufficient high‑quality data are available.

Evidence-informed considerations (no explicit coverage rules provided)

Evidence summaries that would inform coverage determinations (no explicit 'covered' or 'not covered' rules present in this excerpt).

rhBMP‑2 approved use considerations: rhBMP‑2 (Infuse) is FDA‑approved for lumbar fusion (L2–S1); systematic reviews and RCTs show higher fusion rates versus autograft in some settings but also identify increased adverse events for certain uses and off‑label applications (notably cervical fusion), supporting restriction to approved indications and requirement for justification for off‑label use.

Summarizes comparative reviews and FDA safety concerns.

Products with insufficient evidence: Multiple allograft and cell‑based products (eg, Trinity Elite, OsteoAMP, Bio4, PrimaGen) and many ceramic or bioactive glass formulations lack high‑quality comparative evidence or randomized trials; this uncertainty may justify denials, requirement for enrollment in clinical studies, or detailed prior authorization documentation when such products are proposed.

Reflects multiple HTAs and evidence assessments noting limited data and heterogeneity.

Evidence quality and fusion assessment variability: Systematic reviews report heterogeneity in fusion assessment methods, timing, adjunctive biologics, and outcome reporting; lack of standardized fusion endpoints limits interpretation and supports requiring standardized imaging (eg, CT at 12 months) and clear procedural documentation when fusion success is used to justify coverage.

Evidence-supported and limited-use groupings

Summary of situations where clinical evidence supports use:

Supported uses: Use of rhBMP‑2 according to FDA‑approved recommendations (eg, one‑level ALIF with LTcage) is supported by trials and reviews showing acceptable safety and improved fusion performance; several ceramic‑based products (eg, AttraX Putty, MagnetOs Granules, selected biphasic calcium‑phosphate formulations) have randomized or prospective data demonstrating noninferior fusion rates to autograft in instrumented posterolateral or interbody fusion settings.

Based on RCTs and systematic reviews reporting noninferiority or comparable fusion performance.

Limited or heterogeneous evidence: Many ceramic variants, bioactive glass products, and specific commercial formulations have limited long‑term or high‑quality RCT evidence; available data are sometimes industry‑sponsored or heterogeneous, limiting generalizability and supporting cautious, indication‑specific use.

Reflects ECRI, Stempels, Lehr, and other reviews noting variable evidence quality.

Safety cautions for off‑label rhBMP‑2: rhBMP‑2 use in cervical fusion has been associated with life‑threatening complications and FDA public health notifications; off‑label use or inappropriate dosing increases risk and requires careful justification and risk‑benefit assessment.

Interbody cage vs no cage evidence

Findings from systematic reviews/meta-analyses comparing interbody cage use to structural bone graft alone:

Cage outcomes (systematic review): A systematic review and meta‑analysis of 20 studies (1,508 patients) found that interbody cage placement was associated with greater postoperative disc height restoration, greater reduction in back pain (VAS), and higher fusion rates (96.3% with cage versus 90.8% without); no significant differences were observed in reoperation rates, overall complications, ODI improvement, or leg pain.

Johnson et al. 2024 meta‑analysis summarized in policy.

Expandable interbody fusion systems evidence

Summary of evidence and limitations for expandable interbody devices:

Evidence strength for expandable systems: Evidence for expandable interbody fusion systems is predominantly low quality and derived largely from retrospective cohorts, single‑center series, and small studies; systematic reviews and meta‑analyses conclude no clear clinical benefit over static cages and call for adequately powered randomized controlled trials with long‑term follow‑up.

ECRI assessment and multiple systematic reviews conclude low‑quality evidence and recommend RCTs.

Graft materials and guideline positions

Society guidance and clinical reports on graft substitutes and extenders:

Bioactive glass and extenders: Retrospective series and small clinical studies of bioactive glass products (eg, BioSphere Putty, BGS‑7) report favorable radiographic fusion rates and clinical improvement but are limited by study design, small sample sizes, and incomplete long‑term follow‑up; larger, long‑term studies are needed to confirm safety and efficacy.

Policy cites retrospective series and prospective 4‑year follow‑up studies with noted limitations.

Hydroxyapatite/calcium extenders and AANS/NASS positions: Guidance and comparative data support use of hydroxyapatite (HA), HA/b‑TCP combinations, and calcium sulfate preparations as graft extenders or alternatives to autologous iliac crest bone graft (AICB) in selected instrumented posterolateral fusion settings; recommendations vary by level and clinical scenario and emphasize evidence‑based, indication‑specific application.

Reflects AANS/NASS guidance and policy statements regarding HA, b‑TCP, and extenders.

Structural allograft indications: Structural cortical or corticocancellous allograft (fresh‑frozen or freeze‑dried), with or without autograft, is indicated in specified cervical and thoracolumbar reconstructions (eg, ACDF, corpectomy, interbody fusion) per society guidance and clinical reports.

This policy identifies specific products and indications that are considered unproven and not medically necessary for enhancement of spinal fusion due to insufficient evidence of efficacy or safety. Examples include many cell-based allograft products (e.g., those containing MSCs, osteoblasts, or pre-osteoblasts) and human amniotic tissue materials, which the literature characteristically reports as low-quality, biased, or lacking comparative randomized data. Clinical requests for these products should be supported by high-quality evidence; absent that, they are not considered medically necessary under this policy.

Use of rhBMP-2 (InFUSE) for cervical spine fusion is associated with documented life‑threatening adverse events and has prompted FDA safety communications advising against off‑label cervical use. Because of these safety concerns, requests for rhBMP‑2 for cervical indications require strong justification and will typically be considered unsupported unless consistent with FDA‑approved lumbar indications or exceptional circumstances with clear risk‑benefit documentation.

Many off‑label uses of rhBMP‑2 and a broad array of ceramic and bioactive glass products lack sufficient high‑quality evidence to support routine use. Systematic reviews and evidence assessments report heterogeneous study designs, limited randomized data, and inconsistent reporting of clinically meaningful outcomes; consequently, off‑label applications and numerous proprietary ceramic/bioactive glass formulations should be considered investigational or not medically necessary unless robust comparative data are provided.

The policy reiterates that rhBMP‑2 is not recommended for routine cervical fusion and that its established safety profile applies when used per FDA‑approved indications (one‑level ALIF with an approved interbody device for L2–S1). Society guidance likewise discourages routine use of rhBMP‑2 for anterior/posterior cervical fusions, single‑level posterior/posterolateral fusions in healthy adults, and routine pediatric spine fusions; off‑label or inappropriate dosing/indications increase risk and require clear clinical justification.

This Medical Policy is provided for informational purposes and must be applied in the context of the member specific benefit plan document and any applicable federal or state mandates. In the event of conflict, the member’s plan governs. Prior authorization and final coverage determinations should be reconciled with plan language and regulatory requirements before approving products or procedures referenced in this policy.

Cell‑based allograft products and human amniotic tissue materials are listed as unproven and not medically necessary for enhancement of spinal fusion because available studies are largely limited to small cohort series, industry‑sponsored reports, or very low‑quality evidence assessments. Well‑designed randomized trials comparing these products to autograft or other established options are needed to demonstrate safety and effectiveness.

The policy identifies specific commercial products with either no published clinical studies or insufficient evidence (for example, Bio4 and PrimaGen) and notes that other ceramic‑based products and proprietary formulations often lack adequate high‑quality comparative data. Use of these products cannot be concluded as safe and effective based on the current literature and therefore should not be routinely endorsed without additional evidence.

Newer ceramic formulations and bioactive glass products vary substantially by composition and manufacturing, and high‑quality evidence is lacking for many of these formulations. The policy calls out that these products require well‑designed comparative trials with standardized fusion assessment and long‑term outcomes before they can be considered equivalent to autograft or other established graft substitutes.

Expandable interbody fusion systems are considered unproven when the supporting literature is limited to low‑quality retrospective cohorts or single‑center case series without prospective randomized data and long‑term clinical outcomes. Systematic reviews to date have not demonstrated a clear clinical benefit of expandable over static cages and emphasize the need for randomized controlled trials to establish comparative effectiveness.

Procedure, Device, and Regulatory Codes

Applicable CPT/Procedure Codes (reference)CPT

0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral.
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure).
20931	Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure).
20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine

Devices and cleared bone graft products (informational)mixed

OptiMesh	OptiMesh Expandable Interbody Fusion System (FDA 510(k) and De Novo referenced).
Duo	Duo Expandable Interbody Fusion System (FDA 510(k) K210155).
i-FACTOR	i-FACTOR peptide enhanced bone graft (FDA PMA reference, ID 320591).
Bicera	Bicera Resorbable Bone Substitute (FDA 501K K172237).
InFUSE	InFUSE Bone Graft/LT-CAGE (FDA PMA/HDE reference, ID 375525/P000058).

FDA document identifiers citedmixed

DEN200010	FDA De Novo classification reference for OptiMesh Expandable Interbody Fusion System (Sep 2020).
K210155	FDA 510(k) premarket approval document ID for Duo Expandable Interbody Fusion System (Feb 2021).
K014200	FDA 510(k) premarket approval document ID for OptiMesh Expandable Interbody Fusion System (Nov 2003).
320591	PMA ID for i-FACTOR peptide enhanced bone graft (Nov 2015).
375525	Humanitarian Device Exemption ID for InFUSE/MASTERGRAFT (Oct 2008).

Provider Responsibilities, Prior Authorization, and Documentation

Billing Rule

Code reference and potential review

The following procedure and unlisted spine codes are provided for reference and may be reviewed for medical necessity. Listing of a code in this policy does not imply coverage. Benefit coverage and reimbursement are determined by the member specific benefit plan document and applicable laws; codes may be subject to prior review or audit.

Affected codes: 0814T; 20930; 20931; 20939; 22899
Inclusion of a code is not a guarantee of payment — verify member plan

Prior Authorization

Indication‑specific prior authorization for rhBMP-2 and off‑label osteobiologics

Prior authorization is recommended or required for use of rhBMP-2 (Infuse) and other osteobiologics when used outside FDA‑approved indications or for off‑label cervical use. Due to documented safety concerns and FDA warnings for cervical fusion, obtain prior authorization and supply supporting clinical documentation when requesting coverage for non-lumbar or off‑label uses.

Clinical Background

Autologous iliac crest bone grafting remains the clinical gold standard for spinal fusion because it provides osteoconductive, osteoinductive, and osteogenic properties that promote bone healing. Although effective, autograft harvest is associated with donor‑site morbidity; this background supports careful evaluation of substitutes, with preference for options supported by high‑quality evidence before adopting newer or investigational graft materials.

Definitions

Allograft — definition

DefinitionThe transplant of an organ or tissue from one individual to another of the same species with a different genotype (allogeneic graft).

Autograft — definition

DefinitionTissue grafted into a new position in the body of the same individual (autologous graft).

Bone Marrow Aspiration — definition

DefinitionRemoval of a small amount of bone marrow in liquid form for examination or for use as a graft adjunct (bone marrow aspiration).

InFUSE Bone Graft (rhBMP-2) — definition

Policy Revision History

2026-01-01Template UpdateLatest

Policy updated for template changes recorded in the policy history.

OpenPayer

Spinal Fusion and Bone Healing Enhancement Products